ABP 300 works by binding the receptor-binding domain of the SARS-CoV-2 spike protein to block viral interaction with angiotensin-converting enzyme 2 (ACE2) receptors.

In the study, a single dose of ABP 300 blocked infection of SARS-CoV-2 in rhesus monkeys and cleared SARS-CoV-2 in three days when given as a therapeutic. The company demonstrated the protective effect of ABP 300 against lung lesions caused by SARS-CoV-2 in monkeys in both capacities. ABP 300 has also been shown to effectively neutralize SARS-CoV-2 pseudovirus and authentic live virus.

The data from preclinical nonhuman primate studies will support further development of the company's monoclonal antibodies in human subjects. ABP 300 recently completed a phase I dose escalation study in human subjects.

FDA grants Lilly EUA for its COVID-19 mAb
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for Eli Lilly's investigational monoclonal antibody (mAb) therapy,...

Humanigen, DOD develop COVID-19 mAb
Humanigen is working with the Department of Defense (DOD) to advance its lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal...

Novartis COVID-19 mAb fails to meet clinical trial endpoints
Novartis has released new data from an interim analysis of its randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of...

Aridis touts positive preclinical results for COVID-19 mAb treatment
Anti-infective therapies firm Aridis Pharmaceuticals has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel...